Merck KGaA has teamed up with Flagship Pioneering's Valo Health on an ambitious project to apply AI to the discovery of novel drug targets and therapeutics for Parkinson's disease. The partnership ...

Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion. If the $12.50-per-share all-cash deal is completed, it will give ...

With the ink barely dry on one takeover agreement, Novartis has signed another, promising to pay up to $2 billion to acquire ...

We are witnessing a long-awaited transformation in depression care. After decades of incremental change, new therapeutic ...

"Screening is typically recommended for patients with confirmed liver cirrhosis or severe liver disease, since many cases of ...

At its second attempt, Rocket Pharma has won FDA approval for its gene therapy for severe leukocyte adhesion deficiency type ...

AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease ...

Recordati has received an unsolicited takeover offer from private equity group CVC Capital Partners that, if completed, would ...

MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer, ...

The data reveal from the phase 1 INLIGHT study of WVE-007 – an oligonucleotide-based gene-silencing drug designed to switch ...

Every clinical trial is built on the promise that the risk is justified by the strength of the evidence supporting it.

Dizal Pharmaceutical's Zegfrovy has taken the EGFR inhibitor class into new territory after hitting the mark in a phase 3 ...